Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)-Reference-Cited by-同舟云学术

Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)

Published:2022-04-16 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Hassel Jessica C.¹,Schank Timo E.¹,Smetak Heiko²,Mühlbauer Jasmin²,Salzmann Martin¹,Machiraju Devayani¹,Menzer Christian¹,Lang Kristin³⁴,König Laila³⁴,Haefner Matthias F.³⁴,Hülsmeyer Ingrid¹⁵,Kohler Christian⁶,Spang Rainer⁶,Enk Alexander¹,Debus Jürgen³⁴,Beckhove Philipp²

Affiliation:

1. Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg. Germany

2. Regensburg Center for Interventional Immunology, University Hospital Regensburg, Regensburg, Germany

3. Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany

4. Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany

5. The Immune Monitoring Unit, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany

6. Statistical Bioinformatics Department, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany

Funder

Bristol Myers Squibb

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2066609

Reference47 articles.

1. Prognostic factors for survival in melanoma patients with brain metastases

2. Metastatic pattern of malignant melanoma

3. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

4. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

5. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?;Pharmacology & Therapeutics;2024-04

2. Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey;Melanoma Research;2024-03-28

3. The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma—two sides of the same coin?;Frontiers in Immunology;2024-03-18

4. Trial watch: local anesthetics in cancer therapy;OncoImmunology;2024-03-17

5. Neoadjuvant Chemoradiotherapy Upregulates the Immunogenicity of Cold to Hot Tumors in Esophageal Cancer Patients;Annals of Surgery Open;2024-02-02